Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Autoimmune disease	Rho-associated coiled-coil containing protein kinase 2 (ROCK2); IL-17; IL-21	<i>In vitro</i> and mouse studies suggest that inhibiting <i>ROCK2</i> could help treat autoimmune diseases. In cultured human T cells, greater <i>ROCK2</i> expression led to higher levels of proinflammatory IL-21 and IL-17, whereas the ROCK2 inhibitor Eril fasudil prevented the increased levels. In mouse models of autoimmune arthritis and lupus, Eril decreased production of IL-17 and IL-21 and reduced arthritis compared with no treatment. Next steps include developing selective ROCK2 inhibitors. Asahi Kasei Pharma Corp. markets Eril fasudil to treat aneurysm.	Patent pending covering work; available for licensing	Biswas, P.S. <i>et al. J. Clin. Invest.</i> ; published online Aug. 9, 2010; doi:10.1172/JCI42856 Contact: Alessandra B. Pernis, Hospital for Special Surgery, New York, N.Y. e-mail: pernisa@hss.edu
<i>SciBX</i> 3(32); doi:10.1038/scibx.2010.976 Published online Aug. 19, 2010				